perinatologyРоссийский вестник перинатологии и педиатрииRossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)1027-40652500-2228Ltd. “The National Academy of Pediatric Science and Innovation”10.21508/1027-4065-2025-70-5-130-136perinatology-2278Research ArticleКЛИНИЧЕСКИЕ СЛУЧАИCLINICAL CASESКлинический случай мукозита, обусловленного Mycoplasma pneumoniae в сочетании с COVID-19 и реактивацией Эпштейна-Барр вирусной инфекции у ребенкаA clinical case of mucositis in child patient caused by Mycoplasma pneumoniae in combination with COVID-19 and reactivation of Epstein-Barr virus infectionhttps://orcid.org/0000-0002-7853-3312ПозднякВ. А.PozdnyakV. A.

Поздняк Валерий Александрович — к.м.н., ассистент кафедры детских инфекций.

420012, Казань, ул. Бутлерова, д. 49

420012, Kazan

valera.pozdnyak1996@gmail.comhttps://orcid.org/0000-0001-7763-5512ХалиуллинаС. В.KhaliullinaS. V.

Халиуллина Светлана Викторовна — д.м.н., проф. кафедры детских инфекций.

420012, Казань, ул. Бутлерова, д. 49

420012, Kazan

https://orcid.org/0000-0001-9336-4820АглямоваТ. А.AglyamovaT. A.

Аглямова Татьяна Александровна — заместитель главного врача по медицинской части ГАУЗ «Набережно-Челнинская ИБ», врач-инфекционист.

423812, Набережные Челны, Московский пр-кт, д. 85

423812, Naberezhnye Chelny

https://orcid.org/0009-0001-5128-5371ЗиминаА. В.ZiminaA. V.

Зимина Анастасия Владимировна — студентка 5-го курса лечебного факультета.

420012, Казань, ул. Бутлерова, д. 49

420012, Kazan

https://orcid.org/0000-0003-1050-9081АнохинВ. А.AnokhinV. A.

Анохин Владимир Алексеевич — д.м.н., проф., зав. кафедрой детских инфекций.

420012, Казань, ул. Бутлерова, д. 49

420012, Kazan

ФГБОУ ВО «Казанский государственный медицинский университет» Минздрава РоссииРоссияKazan State Medical UniversityRussian FederationГАУЗ «Набережно-Челнинская инфекционная больница»РоссияNaberezhnye Chelny Infectious Diseases HospitalRussian Federation202514112025705130136Copyright © Ltd. “The National Academy of Pediatric Science and Innovation”, 20252025Ltd. “The National Academy of Pediatric Science and Innovation”Ltd. “The National Academy of Pediatric Science and Innovation”https://www.ped-perinatology.ru/jour/about/submissions#copyrightNoticehttps://www.ped-perinatology.ru/jour/article/view/2278

Mycoplasma pneumoniae является одним из наиболее значимых бактериальных патогенов в структуре респираторных инфекций у детей. У 5–10% инфицированных развивается «атипичная» пневмония, в остальных случаях микоплазмоз протекает с клиникой поражения верхних дыхательных путей, нередко в сочетании с внелегочными проявлениями; частота последних может достигать 25%, чаще всего регистрируют поражения кожи и слизистых. Описаны случаи развития артритов, энцефалитов, миелитов, тяжелых анемий, миокардитов и пр. У 60% детей, инфицированных Mycoplasma pneumoniae, возможно развитие ко-инфекции, у каждого пятого это SARS-CoV-2. Мы представляем клиническое наблюдение пациента 16 лет с острой инфекцией дыхательных путей и мукозитом, обусловленным сочетанным инфицированием M.pneumoniae и SARS-CoV-2 на фоне реактивации Эпштейна-Барр вирусной инфекции.

Mycoplasma pneumoniae is one of the most significant bacterial pathogens in the structure of respiratory infections in children. In 5–10% cases the course of disease is “atypical” pneumonia, in other cases, mycoplasmosis occurs with symptoms of upper respiratory tract infection, often in combination with extrapulmonary manifestations; the frequency of the latter can reach 25%, the main are skin and mucous membrane lesions. Cases of arthritis, encephalitis, myelitis, severe anemia, myocarditis etc. are also described among other extrapulmomary manifestations. In 60% of children infected with Mycoplasma pneumoniae there is might becoinfection with other pathogens, in every fifth it is SARS-CoV-2. We present a clinical observation of a 16-year-old patient with acute respiratory tract infection and mucositis caused by combined infection with M.pneumoniae and SARS-CoV-2 with the reactivation of EBV infection.

Mycoplasma pneumoniaeмукозитMIRMMPAMSARS-CoV-2вирус Эпштейна-БаррMycoplasma pneumoniaemucositisMIRMMPAMSARS-CoV-2extrapulmonary manifestationsReferencesGBD 2021 Lower Respiratory Infections and Antimicrobial Resistance Collaborators. Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Infect Dis. 2024; 24(9): 974–1002. DOI: 10.1016/S1473-3099(24)00176-2GBD 2021 Lower Respiratory Infections and Antimicrobial Resistance Collaborators. Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Infect Dis. 2024; 24(9): 974–1002. DOI: 10.1016/S1473-3099(24)00176-2Рачина С.А., Купрюшина О.А., Яснева А.С., Волосовцова Е.С., Стрелкова Д.А., Авдеев С.Н. и др. Что мы знаем о микоплазменной пневмонии? Практическая Пульмонология. 2023;(3): 20–30. DOI: 10.24412/2409-6636-2023-13021Rachina S.A., Kuprjushina O.A., Jasneva A.S., Volosovcova E.S., Strelkova D.A., Avdeev S.N. et al. What Do We Know about Mycoplasmal Pneumonia? Prakticheskaja Pul’monologija. 2023;(3): 20–30 (in Russ.) DOI: 10.24412/2409-6636-2023-13021Korneenko E., Rog I., Chudinov I., Lukona-Gronskaya A., Kozyreva A., Belyaletdinova I. et al. Antibiotic resistance and viral co-infection in children diagnosed with pneumonia caused by Mycoplasma pneumoniae admitted to Russian hospitals during October 2023—February 2024. BMC Infectious Diseases. 2025; 25(1): 363. DOI: 10.1186/s12879-025-10712-0Korneenko E., Rog I., Chudinov I., Lukona-Gronskaya A., Kozyreva A., Belyaletdinova I. et al. Antibiotic resistance and viral co-infection in children diagnosed with pneumonia caused by Mycoplasma pneumoniae admitted to Russian hospitals during October 2023—February 2024. BMC Infectious Diseases. 2025; 25(1): 363. DOI: 10.1186/s12879-025-10712-0Mycoplasma Pneumoniae Infections Have Been Increasing. October 18, 2024. U.S. Centers for Disease Control and Prevention. https://www.cdc.gov/ncird/whats-new/mycoplasma-pneumoniae-infections-have-been-increasing.html. Ссылка активна на 28.05.2025Mycoplasma Pneumoniae Infections Have Been Increasing. October 18, 2024. U.S. Centers for Disease Control and Prevention. https://www.cdc.gov/ncird/whats-new/mycoplasma-pneumoniae-infections-have-been-increasing.html. Ссылка активна на 28.05.2025Kutty P.K., Jain S., Taylor T.H., Bramley A.M., Diaz M.H., Ampofo K. et al. Mycoplasma pneumoniae Among Children Hospitalized With Community-acquired Pneumonia. Clin Infect Dis. 2019; 68(1): 5–12. DOI: 10.1093/cid/ciy419Kutty P.K., Jain S., Taylor T.H., Bramley A.M., Diaz M.H., Ampofo K. et al. Mycoplasma pneumoniae Among Children Hospitalized With Community-acquired Pneumonia. Clin Infect Dis. 2019; 68(1): 5–12. DOI: 10.1093/cid/ciy419Sun Y., Li P., Jin R., Liang Y., Yuan J., Lu Z. et al. Characterizing the epidemiology of Mycoplasma pneumoniae infections in China in 2022–2024: a nationwide cross-sectional study of over 1.6 million cases. Emerg Microbes Infect. 2025; 14(1): 2482703. DOI: 10.1080/22221751.2025.2482703Sun Y., Li P., Jin R., Liang Y., Yuan J., Lu Z. et al. Characterizing the epidemiology of Mycoplasma pneumoniae infections in China in 2022–2024: a nationwide cross-sectional study of over 1.6 million cases. Emerg Microbes Infect. 2025; 14(1): 2482703. DOI: 10.1080/22221751.2025.2482703Kalantar H.T., Pooboni S. Mycoplasma pneumoniae-Induced Erythema Multiforme in an 11-Year-Old Boy: Diagnostic and Therapeutic Challenges. Cureus. 2025; 17(3):e79944. DOI: 10.7759/cureus.79944Kalantar H.T., Pooboni S. Mycoplasma pneumoniae-Induced Erythema Multiforme in an 11-Year-Old Boy: Diagnostic and Therapeutic Challenges. Cureus. 2025; 17(3):e79944. DOI: 10.7759/cureus.79944Mycoplasma pneumoniae infection. Centre for Health Protection, Hong Kong. https://www.chp.gov.hk/en/healthtopics/content/24/21283.html. Ссылка активна на 28.05.2025Mycoplasma pneumoniae infection. Centre for Health Protection, Hong Kong. https://www.chp.gov.hk/en/healthtopics/content/24/21283.html. Ссылка активна на 28.05.2025Lofgren D., Lenkeit C. Mycoplasma Pneumoniae-Induced Rash and Mucositis: A Systematic Review of the Literature. Spartan Med Res J. 2021; 6(2): 25284. DOI: 10.51894/001c.25284Lofgren D., Lenkeit C. Mycoplasma Pneumoniae-Induced Rash and Mucositis: A Systematic Review of the Literature. Spartan Med Res J. 2021; 6(2): 25284. DOI: 10.51894/001c.25284Canavan T.N., Mathes E.F., Frieden I., Shinkai K. Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review. J Am Acad Dermatol. 2015; 72(2): 239–245. DOI: 10.1016/j.jaad.2014.06.026Canavan T.N., Mathes E.F., Frieden I., Shinkai K. Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review. J Am Acad Dermatol. 2015; 72(2): 239–245. DOI: 10.1016/j.jaad.2014.06.026Samir S. Shah. Mycoplasma Pneumoniae. In: Principles and Practice of Pediatric Infectious Diseases 6th Edition. Editors S. Long, C. Prober, M. Fischer, D. Kimberlin. Philadelphia. Elsevier, 2023; 1041–1045Samir S. Shah. Mycoplasma Pneumoniae. In: Principles and Practice of Pediatric Infectious Diseases 6th Edition. Editors S. Long, C. Prober, M. Fischer, D. Kimberlin. Philadelphia. Elsevier, 2023; 1041–1045Marquart E., Kinaciyan T. Overlapping clinical presentation of Mycoplasma-induced rash and mucositis and drug-induced Stevens Johnson Syndrome: A case report. ID Cases. 2023; 33:e01888. DOI: 10.1016/j.idcr.2023.e01888Marquart E., Kinaciyan T. Overlapping clinical presentation of Mycoplasma-induced rash and mucositis and drug-induced Stevens Johnson Syndrome: A case report. ID Cases. 2023; 33:e01888. DOI: 10.1016/j.idcr.2023.e01888Frantz R., Huang S., Are A., Motaparthi K. Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management. Medicina (Kaunas). 2021; 57(9): 895. DOI: 10.3390/medicina57090895Frantz R., Huang S., Are A., Motaparthi K. Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management. Medicina (Kaunas). 2021; 57(9): 895. DOI: 10.3390/medicina57090895Mycoplasma-Induced Rash and Mucositis. American Academy of Ophthalmology. https://eyewiki.org/Mycoplasma-Induced_Rash_and_Mucositis. Ссылка активна на 28.05.2025Mycoplasma-Induced Rash and Mucositis. American Academy of Ophthalmology. https://eyewiki.org/Mycoplasma-Induced_Rash_and_Mucositis. Ссылка активна на 28.05.2025Ramien M.L. Stevens-Johnson syndrome in children. Curr Opin Pediatr. 2022; 34(4): 341–348. DOI: 10.1097/MOP.0000000000001146Ramien M.L. Stevens-Johnson syndrome in children. Curr Opin Pediatr. 2022; 34(4): 341–348. DOI: 10.1097/MOP.0000000000001146Kechichian E., Dupin N., Wetter D.A., Ortonne N., Agbo-Godeau S., Chosidow O. Erythema multiforme. EClinicalMedicine. 2024; 77: 102909. DOI: 10.1016/j.eclinm.2024.102909Kechichian E., Dupin N., Wetter D.A., Ortonne N., Agbo-Godeau S., Chosidow O. Erythema multiforme. EClinicalMedicine. 2024; 77: 102909. DOI: 10.1016/j.eclinm.2024.102909Колганова Н.И., Овсянников Д.Ю., Анджель А.Е., Бирюкова М.В., Гитинов Ш.А., Горев В.В. и др. Внелегочные проявления инфекции, вызванной Mycoplasma pneumoniae, у детей. Детские инфекции. 2024; 23(2 (87)):45–51. DOI: 10.22627/2072-8107-2019-18-3-5-10Kolganova N.I., Ovsjannikov D.Ju., Andzhel’ A.E., Birjukova M.V., Gitinov Sh.A, Gorev V.V. et al. Extrapulmonary manifestations of Mycoplasma pneumoniae infection in children. Detskie Infekcii. 2024; 23(2 (87)):45–51 (in Russ.) DOI: 10.22627/2072-8107-2019-18-3-5-10Bukhari E.E., Alotaibi F.E., Bugshan A.S., Bakheet H.M., Binsufayan S.M., Alsaadi M.M. Mycoplasma pneumoniae-associated mucositis syndrome: A rare and clinically challenging disease in a Saudi child. J Taibah Univ Med Sci. 2017; 12(4): 356–359. DOI: 10.1016/j.jtumed.2016.12.002Bukhari E.E., Alotaibi F.E., Bugshan A.S., Bakheet H.M., Binsufayan S.M., Alsaadi M.M. Mycoplasma pneumoniae-associated mucositis syndrome: A rare and clinically challenging disease in a Saudi child. J Taibah Univ Med Sci. 2017; 12(4): 356–359. DOI: 10.1016/j.jtumed.2016.12.002Zhou Y., Wang J., Chen W., Shen N., Tao Y., Zhao R. et al. Impact of viral coinfection and macrolide-resistant mycoplasma infection in children with refractory Mycoplasma pneumoniae pneumonia. BMC Infect Dis. 2020; 20(1): 633. DOI: 10.1186/s12879-020-05356-1Zhou Y., Wang J., Chen W., Shen N., Tao Y., Zhao R. et al. Impact of viral coinfection and macrolide-resistant mycoplasma infection in children with refractory Mycoplasma pneumoniae pneumonia. BMC Infect Dis. 2020; 20(1): 633. DOI: 10.1186/s12879-020-05356-1Li F., Zhang Y., Shi P., Cao L., Su L., Fu P. et al. Mycoplasma pneumoniae and Adenovirus Coinfection Cause Pediatric Severe Community-Acquired Pneumonia. MicrobiolSpectr.2022; 10(2):e00026–22. DOI: 10.1128/spectrum.00026-22Li F., Zhang Y., Shi P., Cao L., Su L., Fu P. et al. Mycoplasma pneumoniae and Adenovirus Coinfection Cause Pediatric Severe Community-Acquired Pneumonia. MicrobiolSpectr.2022; 10(2):e00026–22. DOI: 10.1128/spectrum.00026-22Song Q., Xu B.P., Shen K.L. Effects of bacterial and viral co-infections of mycoplasma pneumoniae pneumonia in children: analysis report from Beijing Children’s Hospital between 2010 and 2014. Int J Clin Exp Med. 2015; 8(9): 15666–15674Song Q., Xu B.P., Shen K.L. Effects of bacterial and viral co-infections of mycoplasma pneumoniae pneumonia in children: analysis report from Beijing Children’s Hospital between 2010 and 2014. Int J Clin Exp Med. 2015; 8(9): 15666–15674Kim K., Jung S., Kim M., Park S., Yang H.J., Lee E. Global Trends in the Proportion of Macrolide-Resistant Mycoplasma pneumoniae Infections: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022; 5(7):e2220949. DOI: 10.1001/jamanetworkopen.2022.20949Kim K., Jung S., Kim M., Park S., Yang H.J., Lee E. Global Trends in the Proportion of Macrolide-Resistant Mycoplasma pneumoniae Infections: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022; 5(7):e2220949. DOI: 10.1001/jamanetworkopen.2022.20949Mycoplasma pneumoniae Infection Surveillance and Trends. U.S. Centers for disease control and prevention. https://www.cdc.gov/mycoplasma/php/surveillance/index.html#cdcreference_4. Ссылка активна на 28.05.2025Mycoplasma pneumoniae Infection Surveillance and Trends. U.S. Centers for disease control and prevention. https://www.cdc.gov/mycoplasma/php/surveillance/index.html#cdcreference_4. Ссылка активна на 28.05.2025Pereyre S., Goret J., Bebear C. Mycoplasma pneumoniae: Current Knowledge on Macrolide Resistance and Treatment. Front Microbiol. 2016; 7: 974. DOI: 10.3389/fmicb.2016.00974Pereyre S., Goret J., Bebear C. Mycoplasma pneumoniae: Current Knowledge on Macrolide Resistance and Treatment. Front Microbiol. 2016; 7: 974. DOI: 10.3389/fmicb.2016.00974

The authors declare that there are no conflicts of interest present.